Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Gets NY State Lab Permit

NEW YORK (GenomeWeb News) – Sequenom today said that its San Diego lab, the Sequenom Center for Molecular Medicine, has received a clinical laboratory permit from New York Department of Health's Wadsworth Center Clinical Laboratory Evaluation Program.

The permit, Sequenom said, allows it to provide its MaterniT21 Plus test to healthcare professionals in the state of New York, effective Aug. 1. The test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA, and it is intended for use in pregnant women at increased risk for fetal aneuploidy.

Verinata Health, a competitor to Sequenom that is owned by Illumina, announced Friday that it had received its clinical lab permit from New York, enabling the firm to offer its Verifi non-invasive prenatal diagnostic test in the state. The test, also for trisomy 21, 18, and 13 and sex chromosome abnormalities, can now be offered by Verinata in all 50 states.

Sequenom had announced in January 2012 that its earlier version of the test, the MaterniT21, was available through its Sequenom Center for Molecular Medicine in all 50 states in the US, including New York.

In addition to announcing the NY state lab permit, Sequenom also said today that its CLIA lab in North Carolina has received accreditation by the College of American Pathologists.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.